Home Alzheimer’s Disease ROS1+ Metastatic NSCLC Sees Early Benefit With Repotrectinib

ROS1+ Metastatic NSCLC Sees Early Benefit With Repotrectinib

Repotrectinib (TPX-0005), a next-generation tyrosine kinase inhibitor (TKI) with activity against ROS1 and TRK, was able to induce good objective responses as well as maintain a favorable safety profile in patients with non–small cell lung cancer (NSCLC) harboring ROS1 fusions.1

These data from updated preliminary findings of the phase 2 expansion 1 (EXP-1) cohort of the ongoing phase 1/2 TRIDENT-1 clinical trial (NCT03093116) were presented virtually at the 2020 World Conference on Lung Cancer (WCLC) Singapore.

“Preliminary TRIDENT-1 data are very encouraging and support repotrectinib as a potential best-in-class treatment in ROS1-positive advanced NSCLC,” Byoung Chul Cho, MD, PhD, a professor at the Yonsei Cancer Center and Severance Hospital, said in a presentation of the data.

Earlier interim data from a cohort of 11 patients in phase 1 of the TRIDENT-1 trial were…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments